Usha Menon
Overview
Explore the profile of Usha Menon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
436
Citations
14624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Collin L, Cushing-Haugen K, Terry K, Goode E, Wu A, Harris H, et al.
Cancer Epidemiol Biomarkers Prev
. 2025 Feb;
PMID: 40009771
Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of...
2.
Phillips A, Pryor S, Carden A, Torr G, Menon U
Nurse Educ
. 2025 Jan;
PMID: 39837336
Background: The benefits of engaging in regular, intentional gratitude practice have been well studied. Interventions incorporating simple gratitude practices, such as the 3 Good Things exercise, may be ideal for...
3.
Marshall V, Chavez M, Mason T, Extermann M, Simon L, Ligatti J, et al.
J Geriatr Oncol
. 2025 Jan;
16(2):102190.
PMID: 39827698
Introduction: Older adults are often prescribed oral anticancer agents (OAAs). Technology-based interventions may offer medication and symptom support. We aimed to evaluate technology ownership, use, and preferred design features of...
4.
Bedia J, Jacobs I, Ryan A, Gentry-Maharaj A, Burnell M, Singh N, et al.
EBioMedicine
. 2025 Jan;
112:105554.
PMID: 39808947
Background: The ovarian cancer (OC) preclinical detectable phase (PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from...
5.
Letourneau R, Pryor S, Arzola S, Menon U
Nurs Manage
. 2025 Jan;
56(1):16-22.
PMID: 39774081
No abstract available.
6.
Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla M, et al.
Breast Cancer Res
. 2024 Dec;
26(1):189.
PMID: 39734228
Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk...
7.
Madan E, Palma A, Vudatha V, Kumar A, Bhoopathi P, Wilhelm J, et al.
Nat Biotechnol
. 2024 Dec;
PMID: 39653752
Cell competition and fitness comparison between cancer and tumor microenvironment (TME) cells determine oncogenic fate. Our previous study established a role for human Flower isoforms as fitness fingerprints, where the...
8.
Nelson B, Hamilton P, Phung M, Milne K, Harris B, Thornton S, et al.
J Clin Invest
. 2024 Oct;
134(24).
PMID: 39470729
BACKGROUNDDespite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment.METHODSWe evaluated the tumor microenvironment of this...
9.
Sundar S, Agarwal R, Davenport C, Scandrett K, Johnson S, Sengupta P, et al.
Lancet Oncol
. 2024 Oct;
25(10):1371-1386.
PMID: 39362250
Background: Multiple risk-prediction models are used in clinical practice to triage patients as being at low risk or high risk of ovarian cancer. In the ROCkeTS study, we aimed to...
10.
Winn-Deen E, Bortolin L, Gusenleitner D, Biette K, Copeland K, Gentry-Maharaj A, et al.
J Mol Diagn
. 2024 Sep;
26(12):1129-1148.
PMID: 39326669
The low incidence of ovarian cancer (OC) dictates that any screening strategy needs to be both highly sensitive and highly specific. This study explored the utility of detecting multiple colocalized...